Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700495 | 0.83 | GPR35 (0.62) | GPR35MAPTHPGDALDH1A1HSD17B10 | |
| SCHEMBL6840900 | 0.80 | TSHR (0.56) | GPR35MAPTHPGDALDH1A1HSD17B10 | |
| SCHEMBL29479746 | 0.78 | GPR35 (0.67) | GPR35MAPTHPGDALDH1A1HSD17B10 | |
| SCHEMBL9198198 | 0.78 | GPR35 (0.67) | GPR35MAPTHPGDALDH1A1HSD17B10 | |
| SCHEMBL29490141 | 0.78 | GPR35 (0.67) | GPR35MAPTHPGDALDH1A1HSD17B10 | |
| SCHEMBL68980 | 0.78 | GPR35 (0.67) | GPR35MAPTHPGDALDH1A1HSD17B10 | |
| SCHEMBL29562216 | 0.78 | TSHR (0.43) | GPR35MAPTALDH1A1CYP3A4TDP1 | |
| SCHEMBL1298366 | 0.78 | TSHR (0.43) | GPR35MAPTALDH1A1CYP3A4TDP1 | |
| SCHEMBL9865001 | 0.77 | GPR35 (0.64) | GPR35MAPTHPGDALDH1A1HSD17B10 | |
| SCHEMBL1040777 | 0.77 | GPR35 (1.00) | GPR35MAPTHPGDALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025053850-A1 | COVALENT KRAS-BINDING COMPOUNDS FOR MEDICAL TREATMENT | HYKU BIOSCIENCES INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-114524938-B | Polymer, photosensitive resin composition, cured film prepared from polymer and photosensitive resin composition, and electronic element | 江苏三月科技股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-114524938-A | Polymer, photosensitive resin composition, cured film prepared from same and electronic element | 江苏三月科技股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-1963294-B1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| EP-1809332-B1 | COMPOSITIONS FOR MULTI-STEP DELIVERY OF HOT-SPOTS RADIATION TO CANCER CELLS | ONCOLOGIC INC (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20110142756-A1 | Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Precipitates In The Cancer | Rose, David S. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20070297980-A1 | Geldanamycin and Derivatives Inhibit Cancer Invasion and Identify Novel Targets | MICHIGAN STATE UNIVERSITY | 2007-12-27 | — | — | US | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| EP-1809332-A2 | COMPOSITIONS FOR MULTI-STEP DELIVERY OF HOT-SPOTS RADIATION TO CANCER CELLS | Oncologic, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| CN-1997632-A | Geldanamycin and derivatives inhibit cancer invasion and identify novel targets | VAN ANDEL RES INST (US) | 2007-07-11 | — | — | CN | disclosed |
| WO-2007067613-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| EP-1737825-A1 | GELDANAMYCIN AND DERIVATIVES INHIBIT CANCER INVASION AND IDENTIFY NOVEL TARGETS | Van Andel Research Institute (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060018908-A1 | Compositions and methods for treating cancer | ROSE, DAVID STUART | 2006-01-26 | — | — | US | disclosed |
| WO-2006010165-A2 | COMPOSITIONS FOR MULTI-STEP DELIVERY OF HOT-SPOTS RADIATION TO CANCER CELLS | ONCOLOGIC, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005095347-A1 | GELDANAMYCIN AND DERIVATIVES INHIBIT CANCER INVASION AND IDENTIFY NOVEL TARGETS | VAN ANDEL RESEARCH INSTITUTE (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050058652-A1 | Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer | ROSE, DAVID STUART | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070297980-A1 | Geldanamycin and Derivatives Inhibit Cancer Invasion and Identify Novel Targets | MET, HSP90B1, HGFAC | GPR35 3998/4885MAPT 3229/4885HPGD 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.